First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase II clinical trial measuring the effectiveness of the combination of
Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients
and/or those with multiple comorbidities unable to receive standard chemotherapy. This study
will be open approximately 2-3 years. Approximately 36 patients will be enrolled on this
study. The study will begin enrolling at The Cancer Institute of New Jersey, with 17 patients
in the first group. If more than 4 responses are noted, the accrual will continue to 36
patients throughout CINJOG.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborators:
Bristol-Myers Squibb Rutgers Cancer Institute of New Jersey